Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Clicks: 386
ID: 266439
2020
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #51 of 161 articles by views in Lancet (London, England)

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 161 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Reference Key
p2020lancetbaricitinib Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Richardson P;Griffin I;Tucker C;Smith D;Oechsle O;Phelan A;Rawling M;Savory E;Stebbing J;;
Journal Lancet (London, England)
Year 2020
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/32032529
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE covid-19 sars-cov-2 humans pubmed abstract nih national institutes of health national library of medicine pandemics pneumonia letter viral / drug therapy* pmid:32032529 pmc7137985 doi:10.1016/s0140-6736(20)30304-4 peter richardson ivan griffin justin stebbing azetidines / therapeutic use* betacoronavirus / drug effects* coronavirus infections / drug therapy* sulfonamides / therapeutic use*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.